



CALL: 844-800-5377
 FAX: 800-239-0363

REMICADE HOME INFUSION REFERRAL FORM

www.evolutionaryrx.com

Patient Name: _____	Physician Name: _____
Address _____	State Lic #: _____ DEA #: _____
City _____ State _____ Zip _____	NPI #: _____ Specialty: _____
Home Ph: (____) _____ - _____ Work: (____) _____ - _____	Practice Name/Hospital: _____
Cell: (____) _____ - _____ Pt. Soc. Sec #: _____ - _____ - _____	Address: _____
Allergies: _____	City: _____ State: _____ Zip: _____
DOB: ____/____/____ Sex: <input type="checkbox"/> M <input type="checkbox"/> F Weight: ____ <input type="checkbox"/> lb <input type="checkbox"/> kg Height: _____	Doctor Ph: (____) _____ - _____ Fax: (____) _____ - _____
BSA: _____ m ² <input type="checkbox"/> See attached demographic sheet	Nurse/Office Contact: _____

INSURANCE INFORMATION (Complete or Attach Copies of Cards)			
Primary Insurance: _____	Secondary Insurance: _____	Rx Card (PBM): _____	Cardholder First Name: _____
City: _____ State: _____	City: _____ State: _____	PBM BIN: _____	Last Name: _____
Plan #: _____	Plan #: _____	City: _____ State: _____	Employer: _____
Group #: _____	Group #: _____	Group #: _____	ID #: _____
Phone: (____) _____ - _____	Phone: (____) _____ - _____	Phone: (____) _____ - _____	Group #: _____

DIAGNOSIS & STATEMENT OF MEDICAL NECESSITY	
Patient Diagnosis: (Checkmark ICD-10 Code) Ulcerative Colitis <input type="checkbox"/> K51.00 Ulcerative (chronic) pancolitis without complications <input type="checkbox"/> K51.20 Ulcerative (chronic) proctitis without complications <input type="checkbox"/> K51.30 Ulcerative (chronic) rectosigmoiditis without complications <input type="checkbox"/> K51.50 Left-sided colitis without complications <input type="checkbox"/> K51.80 Other ulcerative colitis without complications <input type="checkbox"/> K51.90 Ulcerative colitis, unspecified, without complications <input type="checkbox"/> Has patient been treated previously for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Medication(s): _____ <input type="checkbox"/> Is patient currently on therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Medication(s): _____ <input type="checkbox"/> Will patient stop taking the above medication(s) before starting the new medication? <input type="checkbox"/> Yes <input type="checkbox"/> No, if yes: How long should patient wait before starting the new medication? _____ <input type="checkbox"/> Medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): _____ <input type="checkbox"/> Has patient received a PPD (tuberculosis) Skin Test? <input type="checkbox"/> Yes <input type="checkbox"/> No Results: _____ Prior to initiating treatment and periodically during therapy, patient should be evaluated for active tuberculosis and tested for latent infection.	Crohn's Disease <input type="checkbox"/> K50.00 Crohn's disease of small intestine without complications <input type="checkbox"/> K50.10 Crohn's disease of large intestine without complications <input type="checkbox"/> K50.80 Crohn's disease of both small and large intestine without complications <input type="checkbox"/> K50.90 Crohn's disease, unspecified, without complications

PRESCRIPTION INFORMATION	
<ol style="list-style-type: none"> Assess patient for signs/symptoms of infection; notify MD if present prior to proceeding. Obtain baseline vital signs (T, P, R, BP) First Remicade Infusion: <input type="checkbox"/> Yes <input type="checkbox"/> No Establish Intravenous Access (Peripheral IV) unless patient already has a line (PICC) Does pt already have a line? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, type of line _____ med(s) that is/are infused via that line _____ Remicade to be infused via the existing line? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, wash out period with other med(s) that is/are infused via the same line _____ Labs before infusion: <input type="checkbox"/> AST <input type="checkbox"/> ALT <input type="checkbox"/> Alk Phos <input type="checkbox"/> Tbili <input type="checkbox"/> Albumin <input type="checkbox"/> Lytes <input type="checkbox"/> BUN <input type="checkbox"/> SrCr <input type="checkbox"/> CBC with differential <input type="checkbox"/> CBC without differential <input type="checkbox"/> Other _____ Remicade Dose Calculation: <input type="checkbox"/> Round off to finish 100 mg vial, maximum dose: 10 mg/kg; Dose more than 5 mg/kg should NOT be administered to pt with moderate to severe heart failure Patient's weight in kg _____ (date of weight taken: _____) Starting Dose: <input type="checkbox"/> 5 mg/kg _____ mg IV at wk: 0, 2, 6 (infusion over a period NOT less than 2 hours) Qty: QS <input type="checkbox"/> 3 mg/kg _____ mg IV at wk: 0, 2, 6 (infusion over a period NOT less than 2 hours) <input type="checkbox"/> Other _____ Maintenance Dose: <input type="checkbox"/> (_____ mg/kg) _____ mg IV q _____ wks for _____ infusions (infusion over a period NOT less than 2 hours) Qty: QS <input type="checkbox"/> Other _____ 	<ol style="list-style-type: none"> Flushing: Flush PIV with 3 - 5 ml NaCl 0.9% per nursing agency protocol. Qty: 30 ml <input type="checkbox"/> (optional) Hydration: Start IV with NaCl 0.9% running at 50 ml/hr Qty: #1 x 100 ml
<ol style="list-style-type: none"> Ancillary supplies: for administration of treatment (use 21 gauge or less needle) Pre-Medication: Pre-medicate 30 minutes prior to infusion (optional) <ol style="list-style-type: none"> <input type="checkbox"/> Acetaminophen 650 mg po x 1 Qty: #2 x 325 mg <input type="checkbox"/> Diphenhydramine 25 mg-50 mg <input type="checkbox"/> po <input type="checkbox"/> IVP (rate not to exceed 25mg/minute) Qty: QS (2 x 25mg cap or 50mg/ml) Patient with prior history of infusion reaction, give: Prednisone 50 mg po OR Solu-Medrol 40 mg slow IVP in addition to Diphenhydramine and Acetaminophen <input type="checkbox"/> Prednisone 50 mg po OR <input type="checkbox"/> Solu-Medrol 40 mg slow IVP over several minutes Qty: #5 x 10 mg OR Qty: #1 x 40 mg vial Other: _____ Medication Preparation: <ol style="list-style-type: none"> Reconstitute each vial with 10 ml SWFI (Sterile Water for Infusion), swirl, DO NOT SHAKE Qty: QS 10 ml SWFI Let stand for 5 minutes Dilute the total volume of the reconstituted Remicade solution dose to 250 ml NS, by withdrawing a volume of NS equal to the volume of reconstituted Remicade from the 250 ml NS bag. Gently mix. (Final Concentration: 0.4 mg/ml - 4 mg/ml) Qty: 250 ml NS Use standard IV tubing with in-line, non-pyrogenic, low-protein-binding filter (pore size of 1.2 micron or less). 	

Please See Second Page



REMICADE HOME INFUSION REFERRAL FORM

CALL: 844-800-5377
FAX: 800-239-0363
www.evolutionaryrx.com

Patient Name: _____ DOB ____/____/____

14. Infusion Rate: Set IV rate to infuse 250 ml IV bag over a period not less than 2 hours as tolerated by patient as directed

Table with 2 columns: Time (min) and Infusion Rate. Rows include 15, 15, 15, 15, 30, and Remainder of Infusion (Not less than 2 hours for total infusion time) with corresponding rates of 10, 20, 40, 80, 150, and 250 ml/hr.

Alternative Rate of Infusion: _____

- 15. Monitoring: Monitor patient's vital signs and tolerance every 15-30 minutes. Watch for fever, chills, pruritis, chest pain, BP changes or dyspnea.
a. Check blood pressure, pulse, temperature every 15 min for the first hr then every 30 min until infusion is completed.
b. Hold infusion and notify MD if patient develops fever, chills, rash, hives, or itching
c. Hold infusion and notify MD if signs and symptoms of hypersensitivity occur: urticaria, dyspnea, hypotension, fever, rash, headache, sore throat, myalgia, polyarthralgias, hand and facial edema, dysphagia, pruritus, flushing, angioedema which may have upper airway involvement, chest discomfort, respiratory symptoms.
i. Follow MD's instructions and discontinue infusion for severe reactions.
d. Symptoms related to the method of administration: pruritus, burning, swelling at the site of venipuncture, abscess at the site of venipuncture.
e. Other symptoms: Headache, dizziness, back pain, fatigue.

16. Managing Infusion Related Events:

For Hypersensitivity:

- a. Hold infusion and notify MD
b. Give: Diphenhydramine 25-50 mg IVP (Rate not to exceed 25 mg/min) q 4 hrs prn itching, hives, or rash (maximum dose/day: 400 mg/day). Qty: #3 x 50 mg/ml vial
Acetaminophen 650 mg po x 1 Qty: #2 x 325 mg
Solu-Medrol 125 mg slow IVP (over several minutes) Qty: #1 x 125 mg vial
For Nausea, give Phenergan 25 mg po x 1 IV x 1 Qty: QS (25 mg tab or 25mg/ml)
If hypotension occurs, stop infusion. NOTIFY MD and get an order to use: NS _____ ml (10 ml/kg) IV-bolus. QTY: _____ml
c. Monitor vital signs every 5 - 10 minutes until normal. If reaction is resolved resume infusion by MD's permission at 10 ml/hr and follow the infusion rate schedule as tolerated by patient.

For Anaphylaxis:

- a. If reaction is unresolved or more severe, stop infusion:
b. Call MD and 911
c. Give: Epinephrine (1:1000) 0.5 mg SQ, may repeat q20 minutes x 2 Qty: #3 x 1 ml
d. Monitor vital signs more frequently

- 17. Observe patient for an additional 30 minutes after conclusion of infusion.
18. If vital signs are stable, discontinue IV and discharge patient
19. Monitor signs and symptoms of infection; during and after therapy. Remicade should NOT be given to patient with clinically important, active infection.
20. If patient develops a serious infection, Remicade therapy should be discontinued.
21. Patient Education: Educate patient on Remicade possible side effects, allergic reactions, delayed allergic reactions and when to contact MD.
a. Most common side effects of Remicade: respiratory infections, such as sinus infection and sore throat, headache, rash, coughing, stomach pain
b. Educate patient to contact MD with the following allergic reactions (may occur during or shortly after infusion): hives, difficulty breathing, chest pain, high or low BP, fever, chills.
c. Educate patient about signs and symptoms of delayed allergic reactions which may occur 3 to 12 days after receiving Remicade infusion and notifying MD immediately if the following occur: fever, rash, headache, sore throat, muscle or joint pain, swelling of the face and hands, difficulty swallowing.
22. Laboratory Order: Labs to be drawn and monitored by MD's office unless they are ordered on this form (please see page 1).
a. Discontinue Remicade if LFT more than 5 times upper limit of normal.
b. All necessary tests/labs prior to and/or during Remicade infusion have been done/or will be done by MD's office and EPSrx can start/continue Remicade infusion as soon as receiving the signed order or Remicade home infusion.

Please make necessary changes in the protocol then sign/date and fax both pages back to Evolutionary Pharmacy Solutions at 1-844-800-5377.

Physician's Signature: _____ DAW (Dispense as Written) Date ____/____/____
IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to Evolutionary Pharmacy Solutions using the contact information provided on this coversheet.